抗CD20单克隆抗体提高淋巴瘤细胞对X射线的敏感性  

Anti-CD20 Monclonal Antibody RTX Enhances Radiosensitivity of Lymphoma Cells

作　　者：闵凤玲[1] 刘芬菊[2] 文万信[2] 翟丽佳[1] 周玮[1] 

机构地区：[1]扬州市第一人民医院血液科,江苏扬州225001 [2]苏州大学放射医学与公共卫生学院,江苏苏州215006

出　　处：《中国实验血液学杂志》2010年第3期660-665,共6页Journal of Experimental Hematology

摘　　要：本研究观察抗CD20单克隆抗体制剂利妥昔(RTX)对X射线所致的人淋巴瘤细胞损伤的影响。用SRB法检测细胞存活,FITC-Annexin-V/PI试剂盒测定细胞凋亡,透射电子显微镜观察细胞形态,激光共聚焦显微镜检测胞质内钙离子浓度。结果显示,RTX可明显增强X射线时的肿瘤细胞生长抑制作用(p<0.05);与单照射组比较,RTX可增加辐射诱导的细胞凋亡;透射电子显微镜下可见多种凋亡表现;细胞内[Ca2+]离子明显升高。结论:RTX可提高淋巴瘤细胞对X射线的辐射敏感性,诱导较多细胞的凋亡,并且与细胞内钙离子的变化有关。This study was aimed to investigate the effects of rituximab（ RTX）, a chimeric human anti-CD20 monoclonal antibody, on lymphoma cell injury induced by X ray irradiation. The human Burkitt EBV-infected and moderate radioresistance lymphoma cells （Namalwa） were used in the this study. Cytotoxicity of rituximab combined with X ray irradiation on Namalwa cells was measured by sulforhodamine B （ SRB ） -staining; the apoptosis of Namaiwa cells was detected by flow cytometry with FITC-AnnexinV/PI double staining; the morphologic changes of cells were observed under transmission electron microscope （TEM） and the change of intracellular free calcium level （ [ Ca^2 ＋ ] i） in response to irradiation and rituximab was deterimined by means of the fluorescent dye fluo-3 and confocal microscopy. The results showed that the growth inhibition in Namaiwa cells exposed to irradiation was enhanced by treatment with rituximab. Compared with irradiation alone, rituximab combined with irradiation significantly induced the cell apoptosis and a sustained rise of intracellular free calcium （ [ Ca^2 ＋ ] i ） level in Namalwa cells; the serial apoptotic appearences of cells could be observed under TEM. It is concluded that rituximab can enhance the sensitivity of lymphoma cells on X ray irradiation as to induce cell more apoptosis, in this process the intracellular free calcium （ [ Ca^2 ＋ ] i）, as an intracellular signaling molecule probably plays an important role.

关 键 词：抗CD20单克隆抗体 利妥昔 淋巴瘤细胞 X射线敏感性 

分 类 号：R733.1[医药卫生—肿瘤] R979.1[医药卫生—临床医学]